Mergers and Acquisitions08 May 2026
Bayer has ended a nearly five-year M&A hiatus in its pharma division by acquiring Perfuse Therapeutics for an upfront payment of $300 million, with the total...
Mergers and Acquisitions07 May 2026
Pfizer reported Q1 2026 revenue of $14.5 billion, a 2% increase, and maintained its full-year guidance. The company's long-term strategy focuses on achieving...
Mergers and Acquisitions07 May 2026
Madrigal Pharmaceuticals has entered into an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a clinical-stage small...
Mergers and Acquisitions05 May 2026
UCB is set to acquire immunology specialist Candid Therapeutics in a deal valued at up to $2.2 billion, comprising $2 billion upfront and up to $200 million in...
Mergers and Acquisitions01 May 2026
AstraZeneca is reshaping its pipeline, discontinuing four assets including atuliflapon, an oral FLAP protein inhibitor for moderate to severe asthma, due to...
Mergers and Acquisitions30 Apr 2026
Teva Pharmaceutical has announced the acquisition of privately held Emalex Biosciences for up to $900 million, comprising $700 million upfront and up to $200...
Mergers and Acquisitions30 Apr 2026
Chiesi Group is acquiring KalVista Pharmaceuticals for $1.9 billion, significantly expanding its rare disease portfolio with the oral therapy Ekterly. Ekterly,...
Mergers and Acquisitions30 Apr 2026
Biogen is pivoting its growth strategy towards early-stage assets to build its "next generation" pipeline, as announced by CEO Chris Viehbacher during the...
Mergers and Acquisitions29 Apr 2026
AbbVie has secured an exclusive option to acquire Kestrel Therapeutics for up to $1.45 billion, contingent on Kestrel meeting specific development and...
Mergers and Acquisitions29 Apr 2026
Eli Lilly has partnered with AI biotech Profluent Bio in a research pact potentially worth up to $2.25 billion to develop advanced DNA editing tools. The...
Mergers and Acquisitions29 Apr 2026
Belén Garijo takes over as Sanofi CEO on April 29, facing the critical challenge of preparing the company for life after Dupixent's patent expiry, expected as...
Mergers and Acquisitions28 Apr 2026
Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, marking its third oncology deal in three weeks. The acquisition focuses on Ajax's lead...
Mergers and Acquisitions28 Apr 2026
Sun Pharmaceutical is set to acquire Organon for $11.75 billion in an all-cash transaction, aiming to significantly bolster its global presence in biosimilars...
Mergers and Acquisitions24 Apr 2026
PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, announced the acquisition of a global antiviral asset portfolio. This strategic move...
Mergers and Acquisitions24 Apr 2026
Plus Therapeutics announced the initiation of manufacturing activities and technology transfer with SpectronRx under a Master Services Agreement (MSA) to...
Mergers and Acquisitions24 Apr 2026
Amneal Pharmaceuticals has acquired Kashiv BioSciences in a $1.1 billion deal, comprising $375 million in cash, $375 million in equity, and up to $350 million...
Mergers and Acquisitions23 Apr 2026
Eli Lilly has terminated its partnership with Rigel Pharmaceuticals for two investigational RIPK1 inhibitors, effective June 15. This decision means Lilly will...
Mergers and Acquisitions22 Apr 2026
Tortugas Neuroscience, a new biotech led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, has launched with $106 million in funding. The...
Mergers and Acquisitions22 Apr 2026
Eli Lilly is set to acquire Kelonia Therapeutics for up to $7 billion, including an upfront payment of $3.25 billion, significantly bolstering its presence in...
Mergers and Acquisitions22 Apr 2026
UCB is set to acquire California-based Neurona Therapeutics for an upfront payment of $650 million, with potential milestone payments reaching up to $500...
Mergers and acquisitions27 Oct 2025
Novartis AG will acquire Avidity Biosciences for USD 72.00 per share in cash, valuing the company at approximately USD 12.0 billion. Avidity will sepa...
Mergers and acquisitions22 Oct 2025
Innovent Biologics and Takeda have entered into a global strategic partnership to co-develop and commercialize Innovent's next-generation immuno-oncol...
Mergers and acquisitions16 Oct 2025
Biocon Biologics and Civica expand their partnership to include Insulin Glargine, aiming to increase the availability of affordable insulin for the 38...
Mergers and acquisitions16 Oct 2025
Boehringer Ingelheim and AimedBio have entered into a global collaboration and licensing agreement to develop a novel antibody-drug conjugate (ADC) th...
Mergers and acquisitions09 Oct 2025
Akero Therapeutics, a clinical-stage company focused on metabolic diseases, has entered into a definitive agreement to be acquired by Novo Nordisk for...
Mergers and acquisitions07 Oct 2025
MaxCyte and Moonlight Bio have entered into a Strategic Platform License agreement. Moonlight Bio will utilize MaxCyte’s Flow Electroporation® technol...
Mergers and acquisitions02 Oct 2025
Elutia Inc. has finalized the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation for $88...
Mergers and acquisitions18 Sept 2025
Roche has entered into a definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical company, for up to $3.5 billion. The a...
Mergers and acquisitions09 Sept 2025
Novartis announced its acquisition of Tourmaline Bio, a clinical-stage biopharmaceutical company, for approximately $1.4 billion. The acquisition cen...
Mergers and acquisitions05 Sept 2025
Zydus Lifesciences and Synthon BV have entered into an exclusive licensing and supply agreement for Ozanimod Capsules, a generic version of ZEPOSIA®, ...
Mergers and acquisitions02 Sept 2025
Polpharma Biologics and MS Pharma have signed licensing agreements for the commercialization of three biosimilar candidates: vedolizumab (PB016), ocre...
Mergers and acquisitions02 Sept 2025
Servier and IDEAYA Biosciences announced an exclusive license agreement for darovasertib, a PKC inhibitor, for uveal melanoma treatment outside the US...
Mergers and acquisitions29 Aug 2025
LakeShore Biopharma Co., Ltd. announced the receipt of a revised preliminary non-binding proposal from a consortium (Oceanpine Capital and Crystal Pea...
Mergers and acquisitions26 Aug 2025
AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' bretisilocin, a novel Phase 2 psychedelic compound for treating moderate-to-severe majo...
Mergers and acquisitions20 Aug 2025
AbbVie has completed its acquisition of Capstan Therapeutics, gaining access to CPTX2309, a first-in-class in vivo targeted lipid nanoparticle (tLNP) ...
Mergers and acquisitions14 Aug 2025
AleraCare, a provider of infusion and specialty pharmacy services, and PURE Healthcare, a medical group specializing in treating chronic conditions, a...
Mergers and acquisitions07 Aug 2025
CorMedix Inc. announced a definitive agreement to acquire Melinta Therapeutics LLC for $300 million. This acquisition significantly expands CorMedix's...
Mergers and acquisitions07 Aug 2025
Melinta Therapeutics, a commercial-stage biopharmaceutical company focused on acute and life-threatening illnesses, has been acquired by CorMedix Inc....
Mergers and acquisitions04 Aug 2025
Demetra, a medical company specializing in bone cements and biomaterials, announced the acquisition of OrthoFundamentals, a provider of single-use sol...
Mergers and acquisitions04 Aug 2025
Mallinckrodt plc and Endo, Inc. have completed their merger, forming a global leader in diversified therapeutics. The combined company boasts a broad ...
